Invasive Skin Cancer Treatable With A Cream

Sept. 14, 2009 - PRLog -- Studies of invasive and superficial skin cancers conducted at the Royal London Hospital’s Department of Dermatology show that treatment with a topical skin cream is both safe and effective.

Two clinical trials show compelling evidence of the safety and effectiveness of this cream.  The first trial was a phase III double blind randomized study and the second trial was an open study.

In both studies two daily applications of the cream for a period of 8 weeks resulted in 78% success rates for both invasive and superficial skin cancers.  Success was defined as zero presence of the skin cancer after histological (microscopical) examination of samples extracted from the lesion site by punch biopsy.

Clinical experience established that the cream is safe.  Only local skin irritation and reddening were observed.  Blood and urine samples were analyzed during the study, no changes were observed by the cream therapy.  No systemic (internal) absorption of the active ingredients in the cream was observed.  This is extremely important especially when compared with 5 fluorouracil which is an anticancer drug used to treat skin cancers, is absorbed through the skin into the blood which has proven to be toxic when used with large skin lesions.

The cream used in these successful studies was Curaderm BEC5.  The active ingredients are a standard mixture of glycoalkaloids extracted from the Devil’s Apple or its close family member the Eggplant.

Currently invasive basal cell carcinoma (morpheoic BCC) treatment is confined to surgical removal.

The cosmetic results obtained with the cream are at least comparable or superior to those resulting from surgical excision as shown by the above and many other studies.